Roche Gains 1.5% after CHF9 Billion Breast Cancer Acquisition Drives Bullish Outlook

Shares in Roche Holding Ltd climbed 1.53% to CHF372.40 on Wednesday. The bullish outlook for the stock is now more closely connected to a broad range of sales projections for its breast cancer drug giredestrant.

Roche investor dashboard

The bull case needs CHF9bn

Roche Holding Ltd · SWX:RO bearer share · SWX:ROP participation certificate
Swiss market closed
Market snapshot: Aug. 19, 2026, 17:30 CEST

RO close

CHF 372.40
▲ 1.53% on Aug. 19

Market value

$354.16bn
Ninth-largest non-U.S. company

Trailing P/E

24.30×
Novartis: 24.18×

Dividend yield

2.94%
Market-data indication

Giredestrant peak-sales gap · CHF bn

9.0Morgan Stanley 6.6Consensus +CHF2.4bn / +36%
The forecast gap equals 3.9% of Roche's 2025 group sales.

First-half currency split

MeasureValueCERCHF
Group sales30.36bn+6%−2%
Pharma sales23.63bn+6%−1%
Diagnostics6.74bn+3%−3%
Core operating profit11.86bn+10%−1%
Core EPSCHF10.85+9%−2%
CER = constant exchange rates. The strong franc erased reported growth.

European pharma comparison

CompanyP/EEPS growthYield
Roche24.30×+30.49%2.94%
Novartis24.18×−11.50%2.95%
AstraZeneca24.18×+21.16%2.08%
Novo Nordisk11.43×+5.13%3.95%

ROP analyst targets

ViewTargetRating
18-analyst averageCHF363.92Buy
BernsteinCHF434.50Outperform
Morgan StanleyCHF410.00Overweight
UBSCHF376.00Buy
Goldman SachsCHF365.00Neutral
Targets apply to SWX:ROP, not the thinly traded SWX:RO bearer share.

Investor read-through

Roche's operating engine is growing, but currency hides the gain. The meaningful valuation upside now rests on giredestrant reaching the CHF9 billion bull forecast, rather than the CHF6.6 billion consensus. That makes the November 30 and December 18 FDA decisions the key binary tests.
Near-term watch: FDA timetable updates · Swiss-franc moves · September 28 capital-markets day.
Sources: TradingView, Roche H1 2026, Morgan Stanley via Investing.com, S&P Global consensus via StockAnalysis. Time-sensitive market data: Aug. 19, 2026, 17:30 CEST.
Roche Shares Edge Up After $2.3 Billion Nurix Cancer Pact

Roche Shares Edge Up After $2.3 Billion Nurix Cancer Pact

Roche Holding Ltd. participation certificates listed on SIX traded up 1.07% at CHF 322.20 late Wednesday morning. Investors were eyeing a new $2.3 billion deal with Nurix Therapeutics, bringing Roche a late-stage blood-cancer asset. The stock line now trades as ROP after the company switched from the former ROG Genussscheine in March. Roche’s bearer shares are listed as RO.
10 June 2026
··